Biocon Invests ₹5.48 Crore in Ampin Solar Power SPV to Boost Green Energy Use

1 min read     Updated on 11 Jun 2026, 05:40 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Biocon Limited has invested ₹5,47,60,000 in Ampin C&I Power Twelve Private Limited, a solar power SPV, acquiring 54,76,000 equity shares at ₹10 each, representing a 37.77% undiluted stake expected to reduce to 15.91% on full dilution. AMPIN is setting up a 27.12 MW (DC) solar plant in Karnataka, supporting Biocon's decarbonization goals and captive power requirements under the Electricity Act.

powered bylight_fuzz_icon
42648987

*this image is generated using AI for illustrative purposes only.

Biocon Limited has acquired an equity stake in Ampin C&I Power Twelve Private Limited (AMPIN) to enhance renewable energy consumption and reduce operational costs. The company invested ₹5,47,60,000 towards the subscription of 54,76,000 equity shares at a face value of ₹10 each. This strategic move supports Biocon's decarbonization goals and ensures a captive power status as per the Electricity Act.

The acquisition was disclosed to the stock exchanges on June 10, 2026, under Regulation 30 of the SEBI Listing Regulations. AMPIN, incorporated on April 23, 2025, is a Special Purpose Vehicle formed for the generation and supply of solar power. The entity reported a net worth of ₹120.78 million as on March 31, 2026, with a standalone turnover of nil and a loss after tax of ₹1.28 million for FY 2025-26.

Investment Details

The transaction was executed via cash consideration. Following the investment, Biocon holds 59,76,000 equity shares, representing 37.77% of AMPIN's paid-up share capital on an undiluted basis. However, this percentage is expected to reduce to 15.91% on a fully diluted basis after proposed investments by other entities in AMPIN. The key parameters of the investment are outlined below:

Particulars: Details
Investment Amount: ₹5,47,60,000
Shares Acquired: 54,76,000 equity shares
Face Value: ₹10 each
Current Stake: 37.77% (undiluted)
Post-dilution Stake: 15.91% (fully diluted)

Operational Objectives

AMPIN is engaged in the business of renewable energy generation and is setting up a Solar Power Plant with a capacity of 27.12 MW (DC) in Karnataka. The acquisition is not a related party transaction, and Biocon's promoters have no interest in the target entity. The agreements between Biocon and AMPIN include a Power Purchase Agreement and a Share Purchase, Subscription, and Shareholders Agreement to maintain the captive status required for regulatory compliance.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
+0.33%-0.02%+6.53%+8.96%+17.35%+0.23%

How will the dilution of Biocon's stake to 15.91% impact its ability to maintain captive power status under the Electricity Act?

What is the projected timeline for the commissioning of the 27.12 MW solar power plant in Karnataka?

How significant will the operational cost savings be relative to Biocon's total energy expenditure?

Biocon to host Macquarie's Healthcare Tour plant visit on June 11

0 min read     Updated on 09 Jun 2026, 11:03 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore, serving as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company. The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting.

powered bylight_fuzz_icon
42494508

*this image is generated using AI for illustrative purposes only.

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore. The event will serve as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company.

The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting. This disclosure was made to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30(6) of the SEBI Listing Regulations.

The event details are as follows:

Date Event Type of Interaction Venue
11-Jun-26 Macquarie's Healthcare Tour – Plant Visit Group Bangalore

Rajesh U. Shanoy, Company Secretary and Compliance Officer, signed the intimation on behalf of Biocon Limited. The information is also available on the company's website.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
+0.33%-0.02%+6.53%+8.96%+17.35%+0.23%

What strategic insights might investors gain from the plant visit regarding Biocon's operational efficiency?

How could this interaction influence institutional investor sentiment ahead of Biocon's next earnings report?

What potential market reactions might arise if any unexpected developments are hinted at during the tour?

More News on Biocon

1 Year Returns:+17.35%